Paper41801147
Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial.
Morgan DR and 11 others. Cancer Prev Res (Phila), 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial. Papers, record 41801147. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41801147
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial.
- PubMed
- Publication types
- Journal Article, Randomized Controlled Trial, Clinical Trial, Phase II, Research Support, U.S. Gov't, Non-P.H.S., Research Support, N.I.H., Extramural
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Stomach Neoplasms | Major topic |
| Helicobacter Infections | Major topic |
| Precancerous Conditions | Major topic |
| Eflornithine | Major topic |
| Humans | |
| Female | |
| Middle Aged | |
| Double-Blind Method | |
| Adult | |
| Helicobacter pylori | |
| Male | |
| Aged | |
| Metaplasia | |
| Follow-Up Studies |
Source PubMed
Grants25
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P01 CA028842 | NCI NIH HHS | United States | P01CA028842 | PubMed | NIH RePORTER |
| 5S21MD000242 | National Institute on Minority Health and Health Disparities (NIMHD) | S21MD000242 | PubMed | NIH RePORTER | |
| I01 CX002473 | CSRD VA | United States | I01CX002473 | PubMed | NIH RePORTER |
| P30 DK058404 | NIDDK NIH HHS | United States | P30DK058404 | PubMed | NIH RePORTER |
| U54 MD007587 | NIMHD NIH HHS | United States | U54MD007587 | PubMed | NIH RePORTER |
| S21 MD000138 | NIMHD NIH HHS | United States | S21MD000138 | PubMed | NIH RePORTER |
| R25MD007607 | National Institute on Minority Health and Health Disparities (NIMHD) | R25MD007607 | PubMed | NIH RePORTER | |
| MD007587 | National Institute on Minority Health and Health Disparities (NIMHD) | PubMed | PubMed | ||
| R01 CA190612 | NCI NIH HHS | United States | R01CA190612 | PubMed | NIH RePORTER |
| I01CX002171 | U.S. Department of Veterans Affairs (VA) | I01CX002171 | PubMed | NIH RePORTER | |
| R25 MD007607 | NIMHD NIH HHS | United States | R25MD007607 | PubMed | NIH RePORTER |
| U54 CA096297 | NCI NIH HHS | United States | U54CA096297 | PubMed | NIH RePORTER |
| CA096297/CA096300 | National Cancer Institute (NCI) | PubMed | PubMed | ||
| S21 MD001830 | NIMHD NIH HHS | United States | S21MD001830 | PubMed | NIH RePORTER |
| R01CA190612 | National Cancer Institute (NCI) | R01CA190612 | PubMed | NIH RePORTER | |
| S21MD001830 | National Institute on Minority Health and Health Disparities (NIMHD) | S21MD001830 | PubMed | NIH RePORTER | |
| P01CA116087 | National Cancer Institute (NCI) | P01CA116087 | PubMed | NIH RePORTER | |
| P01 CA116087 | NCI NIH HHS | United States | P01CA116087 | PubMed | NIH RePORTER |
| P01CA028842 | National Cancer Institute (NCI) | P01CA028842 | PubMed | NIH RePORTER | |
| P30CA068485 | National Cancer Institute (NCI) | P30CA068485 | PubMed | NIH RePORTER |
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT02794428 | Chemoprevention of Gastric Carcinogenesis | Results | Yes |
Source ClinicalTrials.gov
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 42381434 | Advancing Gastric Cancer Chemoprevention: Early Signals and Ongoing Challenges. | https://conductscience.org/library/papers/42381434 |
Source PubMed
References57
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30573307 | High prevalence of non-alcoholic fatty liver disease and metabolic risk factors in Guatemala: A population-based study. | Nutr Metab Cardiovasc Dis | 2019 | https://conductscience.org/library/papers/30573307 | PubMed |
| 2 | 23403682 | Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities. | JAMA | 2013 | https://conductscience.org/library/papers/23403682 | PubMed |
| 3 | 1557457 | Malignant melanoma. | Plast Surg Nurs | 1992 | https://conductscience.org/library/papers/1557457 | PubMed |
| 4 | 16519678 | Inhibition of polyamine and spermine oxidases by polyamine analogues. | FEBS J | 2006 | https://conductscience.org/library/papers/16519678 | PubMed |
| 5 | 24868089 | At the Bench: Helicobacter pylori, dysregulated host responses, DNA damage, and gastric cancer. | J Leukoc Biol | 2014 | https://conductscience.org/library/papers/24868089 | PubMed |
| 6 | 20600019 | Polyamines Impair Immunity to Helicobacter pylori by Inhibiting L-Arginine Uptake Required for Nitric Oxide Production. | Gastroenterology | 2010 | https://conductscience.org/library/papers/20600019 | PubMed |
| 7 | 33688342 | Gastric Intestinal Metaplasia: Demographic and Epidemiological Characterization in Puerto Rican Hispanics (2012-2014). | Gastroenterol Res Pract | 2021 | https://conductscience.org/library/papers/33688342 | PubMed |
| 8 | 31484660 | Efficacy of Difluoromethylornithine and Aspirin for Treatment of Adenomas and Aberrant Crypt Foci in Patients with Prior Advanced Colorectal Neoplasms. | Cancer Prev Res (Phila) | 2019 | https://conductscience.org/library/papers/31484660 | PubMed |
| 9 | 40072512 | Gastric Cancer Screening in the United States: A Review of Current Evidence, Challenges, and Future Perspectives. | Am J Gastroenterol | 2025 | https://conductscience.org/library/papers/40072512 | PubMed |
| 10 | 35785449 | Racial/ethnic disparities in gastric cancer: A 15-year population-based analysis. | Cancer Med | 2023 | https://conductscience.org/library/papers/35785449 | PubMed |
| 11 | 21777974 | 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. | Lancet | 2011 | https://conductscience.org/library/papers/21777974 | PubMed |
| 12 | 15247269 | Induction of polyamine oxidase 1 by Helicobacter pylori causes macrophage apoptosis by hydrogen peroxide release and mitochondrial membrane depolarization. | J Biol Chem | 2004 | https://conductscience.org/library/papers/15247269 | PubMed |
| 13 | 37415099 | Use of research electronic data capture (REDCap) in a sequential multiple assignment randomized trial (SMART): a practical example of automating double randomization. | BMC Med Res Methodol | 2023 | https://conductscience.org/library/papers/37415099 | PubMed |
| 14 | 39614759 | Evaluating Difluoromethylornithine Safety and Efficacy for Non-Melanoma Skin Cancer Chemoprevention: A Systematic Review. | J Cutan Med Surg | 2025 | https://conductscience.org/library/papers/39614759 | PubMed |
| 15 | 38572751 | Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. | CA Cancer J Clin | 2024 | https://conductscience.org/library/papers/38572751 | PubMed |
| 16 | 38033490 | Eflornithine for chemoprevention in the high-risk population of colorectal cancer: a systematic review and meta-analysis with trial sequential analysis. | Front Oncol | 2023 | https://conductscience.org/library/papers/38033490 | PubMed |
| 17 | 15313165 | Mouse spermine oxidase: a model of the catalytic cycle and its inhibition by N,N1-bis(2,3-butadienyl)-1,4-butanediamine. | Biochem Biophys Res Commun | 2004 | https://conductscience.org/library/papers/15313165 | PubMed |
| 18 | 36493697 | The nutraceutical electrophile scavenger 2-hydroxybenzylamine (2-HOBA) attenuates gastric cancer development caused by Helicobacter pylori. | Biomed Pharmacother | 2023 | https://conductscience.org/library/papers/36493697 | PubMed |
| 19 | 33220252 | The Colombian Chemoprevention Trial: 20-Year Follow-Up of a Cohort of Patients With Gastric Precancerous Lesions. | Gastroenterology | 2021 | https://conductscience.org/library/papers/33220252 | PubMed |
| 20 | 39523394 | Spermine oxidase promotes Helicobacter pylori-mediated gastric carcinogenesis through acrolein production. | Oncogene | 2025 | https://conductscience.org/library/papers/39523394 | PubMed |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| EFLORNITHINE | CHEMBL830 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL830 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Cited by
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41801147
GET https://conductscience.org/api/papers/v1/41801147/grants?page=2